Skip to main content
Narrative Book
01Path To Agi
02⚠️Geopolitics
03Conflict
04Climate
05📈Tech
06🔍Health
07🔴Ai In War
08₿Crypto
09💰Follow The Money
10📡Info Warfare
11👁Silent Companies
12🛰Space Dominance
13💧Water Security
14🤯Wtf
15🔔Whistleblowers
16🧪Synthetic Bio
17🌐Digital Nations
18🚀Sci-Fi → Real
19🔴System Failures
20🕵️Conspiracies ✓
21📊MOST INTERES…
22📜MIND BENDING…
23🏛GLOBAL LOBBY…
24📈INTERESTING …
25⚖Dirty Politics
26📉DALIO PRINCI…
🧬

BREAKTHROUGH

Healthcare & Medical

Central Hypothesis

“Track clinical evidence, approvals, safety signals, and real-world outcomes for major medical developments.”
Evidence strength · confident
28 sourced findings·3 corroborated
76%
6.1Game-Changing Innovations
1476

FDA approvals now dominate the card: first treatments for Alexander disease and glycogen storage disease, expanded pediatric access for Casgevy, and early RNA, DNA vaccine, and engineered-virus studies mark a shift from experimental platforms toward targeted clinical use.

🥇
TRL
9
✅ Approved
🥈
TRL
5
🥉
✂️
TRL
5
✂️
TRL
5
✂️
TRL
5
✂️
TRL
5
TRL
6
Ph1
💉
TRL
5
TRL
5
💊
TRL
5
💉
TRL
6
Ph1
TRL
9
✅ Approved
✂️
TRL
5
✂️
TRL
9
✅ Approved
6.2Disease Cure Frontiers
474

mRNA platform expansion enables 100-day vaccine response targets. Global surveillance gaps remain.

bar = value against the largest on this card
MetricValueDetail
In-body CRISPR delivery🔴 SPOF
Al3Cas12f more than 80%…
▾
MetricIn-body CRISPR delivery
ValueAl3Cas12f RKK: more than 80% editing efficiency across tested targets, reaching 90% in one region; small enough for AAV-vector delivery research (NIH, 2026-04-13)
DetailCAUSAL: (1) NIH-funded researchers identified and enhanced a small Cas12f enzyme and reported editing efficiency rising from less than 10% to more than 80% across tested targets in human cells. (2) Its small size fits adeno-associated-virus vectors, addressing the size constraint that has limited in-body delivery; the team planned AAV packaging tests next. (3) This implies a delivery bottleneck for gene-editing therapies is being attacked at the enzyme-design level, but the evidence remains preclinical and the source does not report a human treatment.
76
nih.gov
FDA Expedited IND Pilot
FDA finalized the pilot on…
▾
MetricFDA Expedited IND Pilot
ValueFDA finalized the pilot on 2026-09-15 and began accepting applications; sponsor and qualified research institution pairs receive rolling pre-IND review intended to shorten the path to first-in-human trials, with 8 to 10 pairs planned for the initial cohort (FDA, 2026-09-15)
DetailCAUSAL: (1) FDA launched a pilot that accepts drug sponsors and qualified research institutions as paired applicants and reviews IND components on a rolling basis before the full submission. (2) Resolving application issues earlier and coordinating institutional review board work and site activation is intended to reduce delays before first-in-human studies, while FDA retains authority over
75
fda.gov
Two fatal Chinese gene-therapy trials
Two children died in separate…
▾
MetricTwo fatal Chinese gene-therapy trials
ValueTwo children died in separate Chinese experimental gene-editing trials; one death followed an AAV treatment for Duchenne muscular dystrophy and the other followed a spinal AAV treatment for a rare neurodevelopmental disorder (Nature, 2026-09-08)
DetailCAUSAL: (1) Two previously undisclosed pediatric deaths were reported in separate Chinese gene-editing trials, one involving Duchenne muscular dystrophy and one involving a rare neurodevelopmental disorder. (2) Both treatments used AAV delivery; the reports describe acute respiratory distress in the Duchenne case, a severe immune reaction in the other case, and investigations into ethics
72
nature.com
Genome-editing safety assessment
FDA draft guidance issued…
▾
MetricGenome-editing safety assessment
ValueFDA draft guidance issued 2026-04-14: standardized next-generation sequencing recommendations for off-target edits and loss of genome integrity in IND and BLA submissions covering ex vivo and in vivo therapies (FDA, 2026-04-14)
DetailCAUSAL: (1) FDA issued draft guidance for human gene therapies using genome editing, specifying sequencing strategies, sample selection, analysis parameters, and reporting. (2) The framework targets two failure modes that could turn a curative edit into a new harm: unintended edits outside the target and loss of chromosome integrity; it applies before clinical testing and licensing to both cells
71
fda.gov
6.3Longevity & Anti-Aging Therapeutics1 live
180

Senolytics and epigenetic reprogramming enter clinical trials. Regulatory classification debated.

bar = value against the largest on this card
MetricValueDetail
ER-100 partial cellular reprogramming
ClinicalTrials.gov lists the…
▾
MetricER-100 partial cellular reprogramming
ValueClinicalTrials.gov lists the ER-100 first-in-human Phase 1 study as recruiting, with an actual study start of 2026-03-02 and planned enrollment of 18 adults with glaucoma or NAION (ClinicalTrials.gov, 2026-09-14)
DetailCAUSAL: (1) ER-100 has moved beyond FDA clearance into an actively recruiting first-in-human Phase 1 study with an actual March 2, 2026 start date. (2) The trial uses sequential dose escalation and expansion cohorts, with safety and tolerability as primary outcomes, and delivers OSK instructions through a modified AAV vector to retinal cells.
80x1
clinicaltrials.gov
6.4Global Drug Pipeline
172

AI-era therapies progressing through clinical stages. Tracking drugs from discovery to market approval.

2026
MMA-101
6.5Pandemic Preparedness
180

WHO 100-day vaccine target drives investment. Genomic surveillance covers 64% of nations. Stockpile gaps remain critical.

Ebola disease outbreak (Bundibugyo virus) in DRC and Uganda with no licensed vaccine or therapeutic— increasing↑ RISING
critical
0255075100
J
F
M
A
M
J
J
A
S
O
N
D

CAUSAL: (1) WHO declared a public health emergency of international concern (PHEIC) on 17 May 2026 for Ebola disease caused by Bundibugyo virus in DRC

▾
RiskEbola disease outbreak (Bundibugyo virus) in DRC and Uganda with no licensed vaccine or therapeutic
Severitycritical
Trendincreasing
DetailCAUSAL: (1) WHO declared a public health emergency of international concern (PHEIC) on 17 May 2026 for Ebola disease caused by Bundibugyo virus in DRC and Uganda; by the Director-General's 2 September 2026 briefing the epidemic had passed 6,000 cases and 3,000 deaths, making it the second-largest Ebola epidemic on record and, per WHO, 'the fastest-moving that we have ever seen,' with Ituri province accounting for 85% of cases. (2) Unlike Zaire ebolavirus, there is no licensed vaccine or specific therapeutic for Bundibugyo virus, so the response depends on supportive care, contact tracing and safe burials in a region already destabilized by conflict and displacement; WHO reports most deaths are occurring in communities rather than treatment centers, with unknown transmission chains still being found, while two candidate vaccines only entered safety trials in the UK and Canada this year and efficacy trials in DRC are not expected to start until October or November 2026. (3) This confirms the card's 'stockpile gaps remain critical' claim directly: the global emergency vaccine stockpile architecture (built for Ebola Zaire, cholera, meningitis and yellow fever) has no product ready for this specific virus, showing WHO's 100-day countermeasure ambition is far from met months into a PHEIC-level outbreak.
80
who.int
6.6Mental Health Crisis
172

Global mental health burden rising. Treatment gap exceeds 75% in low-income countries. Youth crisis accelerating post-pandemic.

bar = value against the largest on this card
MetricValueDetail
FDA psychedelic-treatment development push
FDA announced 3 national…
▾
MetricFDA psychedelic-treatment development push
ValueFDA announced 3 national priority vouchers and cleared a U.S. phase I noribogaine study for serious mental illness and substance-use disorders (FDA, 2026-04-24)
DetailCAUSAL: (1) On 24 April 2026, FDA announced national priority vouchers for three programs studying psilocybin for treatment-resistant depression, psilocybin for major depressive disorder, and methylone for PTSD, while also allowing a phase I U.S. clinical study of noribogaine hydrochloride for alcohol use disorder to proceed.
72
fda.gov
6.7Antimicrobial Resistance2 live
380

AMR kills 1.27M/yr directly. Pipeline inadequate. AI-discovered compounds offer hope but market incentives broken.

Antibiotic discovery pipeline gap for multidrug-resistant Gram-negative pathogens— new↑ RISING
critical
0255075100
J
F
M
A
M
J
J
A
S
O
N
D

CAUSAL: (1) WHO's updated surveillance reports that approximately one in six laboratory-confirmed bacterial infections worldwide were resistant to ant

▾
RiskAntibiotic discovery pipeline gap for multidrug-resistant Gram-negative pathogens
Severitycritical
Trendnew
DetailCAUSAL: (1) WHO's updated surveillance reports that approximately one in six laboratory-confirmed bacterial infections worldwide were resistant to antibiotics in 2023, and resistance increased in more than 40% of monitored pathogen-antibiotic combinations from 2018 to 2023, with average annual increases of 5% to 15%.
84x1
who.int
Antimicrobial resistance: implementation gap for the 2026-2036 global action plan— increasing↑ RISING
high
0255075100
J
F
M
A
M
J
J
A
S
O
N
D

CAUSAL: (1) WHO reports that one in six laboratory-confirmed bacterial infections worldwide were resistant in 2023, and that resistance increased in o

▾
RiskAntimicrobial resistance: implementation gap for the 2026-2036 global action plan
Severityhigh
Trendincreasing
DetailCAUSAL: (1) WHO reports that one in six laboratory-confirmed bacterial infections worldwide were resistant in 2023, and that resistance increased in over 40% of monitored pathogen-antibiotic combinations from 2018 to 2023, with average annual increases of 5% to 15%.
84x1
who.int
Limited oral options for complicated urinary tract infections— new↑ RISING
high
0255075100
J
F
M
A
M
J
J
A
S
O
N
D

CAUSAL: (1) FDA approved Utebzi, the first oral carbapenem for complicated urinary tract infections, including pyelonephritis, in adults with limited

▾
RiskLimited oral options for complicated urinary tract infections
Severityhigh
Trendnew
DetailCAUSAL: (1) FDA approved Utebzi, the first oral carbapenem for complicated urinary tract infections, including pyelonephritis, in adults with limited or no alternative oral treatment options. (2) In a global randomized noninferiority trial of 1,690 hospitalized patients, oral Utebzi had effectiveness comparable to intravenous imipenem-cilastatin; the indication covers susceptible microorganisms
73
fda.gov
6.8Health Equity & Access
180

Global health disparities widening. Universal healthcare coverage at 47%. Vaccine equity remains unresolved.

bar = value against the largest on this card
MetricValueDetail
Global mpox vaccine equity mechanism
Global mpox vaccine…
▾
MetricGlobal mpox vaccine equity mechanism
ValueGlobal mpox vaccine stockpile: launched 27 Aug 2026 under the ICG mechanism; covers 145 countries/territories that reported 190,683 mpox cases since Jan 2022 (WHO/Gavi, 2026-09-02)
DetailCAUSAL: (1) On 27 August 2026, Gavi, WHO, UNICEF, IFRC and MSF launched a permanent global stockpile of mpox vaccines, approved by Gavi's Board in 2025 and coordinated through the International Coordinating Group (ICG) on Vaccine Provision, replacing the ad hoc Access and Allocation Mechanism used during the 2024 mpox PHEIC. (2) The ICG has managed pooled emergency vaccine stockpiles for cholera, meningitis, yellow fever and Ebola since 1997; extending it to mpox creates a standing, pre-funded allocation channel so access depends on outbreak need rather than a country's ability to pay; Gavi's CEO stated lower-income countries were 'left behind' on vaccine access during the 2022 mpox emergency, and two-thirds of the 190,683 confirmed cases reported globally from January 2022 to July 2026 have occurred in the African Region. (3) This is a direct institutional response to the card's 'vaccine equity remains unresolved' claim, converting a one-off crisis mechanism into permanent global health infrastructure for one disease, though it does not itself move the card's broader 47% universal-health-coverage figure, since it addresses vaccine allocation only, not health-system access generally.
80
who.int
6.9Digital Health & Telemedicine
174

Telemedicine adoption permanent post-COVID. AI diagnostics matching specialists in 12 conditions. Wearable health data exploding.

bar = value against the largest on this card
MetricValueDetail
TEMPO real-world digital-health evidence pilot
FDA selected Dexcom as first…
▾
MetricTEMPO real-world digital-health evidence pilot
ValueFDA selected Dexcom as first participant on 2026-07-22; glucose program uses real-time data and AI insights within CMS ACCESS (FDA, 2026-07-22)
DetailCAUSAL: (1) FDA selected Dexcom's Glucose Health Program as the first participant in the Technology-Enabled Meaningful Patient Outcomes (TEMPO) pilot, linked to CMS's ACCESS model for chronic-disease care. (2) The program is intended to let patients, clinicians and caregivers monitor metabolic and nutritional status, receive tailored guidance, and use real-time data and AI insights; TEMPO
74
fda.gov
6.10Biotech Investment Landscape
175

Biotech VC rebounds with AI-drug discovery focus. IPO window reopening. M&A activity surges as big pharma acquires innovation.

bar = value against the largest on this card
MetricValueDetail
Frontier AI as biotech acquirer
Nature Biotechnology reported…
▾
MetricFrontier AI as biotech acquirer
ValueNature Biotechnology reported 2026-07-07 that frontier AI and big tech companies are acquiring early-stage biology foundational platforms; the emerging exit path is distinct from traditional pharma acquisition (Nature, 2026-07-07)
DetailCAUSAL: (1) A Nature Biotechnology comment identifies a new class of biotech buyer: frontier AI and big tech companies acquiring early-stage biology foundational platforms, with Anthropic's approximately $400 million Coefficient Bio acquisition cited in the references.
75
nature.com
▸Verified Sources (170)

This topic's hunt pipeline cites only these 170 domains — no general web sources.

Government / Regulator

  • U.S. CDC — cdc.gov
  • U.S. NIH — nih.gov
  • U.S. FDA — fda.gov
  • ClinicalTrials.gov — clinicaltrials.gov
  • European Medicines Agency — ema.europa.eu
  • European CDC — ecdc.europa.eu
  • U.S. Department of Health and Human Services — hhs.gov
  • Agency for Healthcare Research and Quality — ahrq.gov
  • Centers for Medicare & Medicaid Services — cms.gov
  • Health Resources and Services Administration — hrsa.gov
  • Substance Abuse and Mental Health Services Administration — samhsa.gov
  • U.S. Preventive Services Task Force — uspreventiveservicestaskforce.org
  • National Health Service — nhs.uk
  • National Institute for Health and Care Excellence — nice.org.uk
  • Medicines and Healthcare products Regulatory Agency — mhra.gov.uk
  • UK Health Security Agency — ukhsa.gov.uk
  • Australian Government Department of Health and Aged Care — health.gov.au
  • Japan Ministry of Health, Labour and Welfare — mhlw.go.jp
  • Singapore Ministry of Health — moh.gov.sg
  • Robert Koch Institute — rki.de
  • Santé publique France — santepubliquefrance.fr

International Organisation

  • World Health Organization — who.int
  • UNAIDS — unaids.org
  • Gavi, the Vaccine Alliance — gavi.org
  • The Global Fund — globalfund.org

Research / Journal

  • New England Journal of Medicine — nejm.org
  • The Lancet — thelancet.com
  • The BMJ — bmj.com
  • JAMA Network — jamanetwork.com
  • Nature — nature.com
  • Science (AAAS) — science.org
  • Cell Press — cell.com
  • medRxiv — medrxiv.org
  • bioRxiv — biorxiv.org
  • PubMed / NCBI — ncbi.nlm.nih.gov
  • Europe PMC — europepmc.org
  • Proceedings of the National Academy of Sciences — pnas.org
  • PLOS — plos.org
  • eLife — elifesciences.org
  • Royal Society Publishing — royalsocietypublishing.org
  • Annals of Internal Medicine — annals.org
  • Journal of Clinical Investigation — jci.org

Primary Lab / Company

  • French National Institute of Health and Medical Research — inserm.fr
  • Institut Pasteur — pasteur.fr

Statistical / Data Agency

  • ISRCTN Registry — isrctn.com
  • Australian New Zealand Clinical Trials Registry — anzctr.org.au

Non-Profit / Archive

  • Cochrane — cochrane.org
  • American Association for Cancer Research — aacr.org
  • American College of Physicians — acponline.org
  • Association of American Medical Colleges — aamc.org

Applies to all topics (120)

  • United Nations — un.org
  • World Bank — worldbank.org
  • IMF — imf.org
  • OECD — oecd.org
  • European Commission — ec.europa.eu
  • U.S. Congress — congress.gov
  • U.S. GAO — gao.gov
  • U.S. National Academies — nationalacademies.org
  • UNESCO — unesco.org
  • UN Environment Programme — unep.org
  • UN Development Programme — undp.org
  • International Telecommunication Union — itu.int
  • World Intellectual Property Organization — wipo.int
  • World Meteorological Organization — wmo.int
  • International Atomic Energy Agency — iaea.org
  • International Civil Aviation Organization — icao.int
  • International Maritime Organization — imo.org
  • UN Food and Agriculture Organization — fao.org
  • International Labour Organization — ilo.org
  • UNCTAD — unctad.org
  • UN Human Rights Office — ohchr.org
  • UN Refugee Agency — unhcr.org
  • International Organization for Migration — iom.int
  • UN Office on Drugs and Crime — unodc.org
  • UNICEF — unicef.org
  • World Food Programme — wfp.org
  • World Trade Organization — wto.org
  • Bank for International Settlements — bis.org
  • Financial Action Task Force — fatf-gafi.org
  • IPCC — ipcc.ch
  • International Renewable Energy Agency — irena.org
  • International Energy Agency — iea.org
  • African Union — au.int
  • ASEAN — asean.org
  • Organization of American States — oas.org
  • CARICOM — caricom.org
  • Pacific Islands Forum — forumsec.org
  • African Development Bank — afdb.org
  • Asian Development Bank — adb.org
  • Inter-American Development Bank — iadb.org
  • Asian Infrastructure Investment Bank — aiib.org
  • EBRD — ebrd.com
  • Council of Europe — coe.int
  • OSCE — osce.org
  • South Africa Government — gov.za
  • Statistics South Africa — statssa.gov.za
  • South African Reserve Bank — resbank.co.za
  • Central Bank of Nigeria — cbn.gov.ng
  • Kenya National Bureau of Statistics — knbs.or.ke
  • Central Bank of Kenya — centralbank.go.ke
  • Bank of Ghana — bog.gov.gh
  • Central Bank of Egypt — cbe.org.eg
  • Bank Al-Maghrib (Morocco) — bkam.ma
  • Rwanda National Institute of Statistics — statistics.gov.rw
  • Government of China — gov.cn
  • China National Bureau of Statistics — stats.gov.cn
  • People's Bank of China — pbc.gov.cn
  • Japan Ministry of Foreign Affairs — mofa.go.jp
  • Statistics Bureau of Japan — stat.go.jp
  • Bank of Japan — boj.or.jp
  • Government of South Korea — korea.kr
  • Bank of Korea — bok.or.kr
  • Statistics Korea — kostat.go.kr
  • Government of India — india.gov.in
  • Reserve Bank of India — rbi.org.in
  • India Ministry of Statistics — mospi.gov.in
  • Press Information Bureau of India — pib.gov.in
  • Government of Singapore — gov.sg
  • Monetary Authority of Singapore — mas.gov.sg
  • Singapore Department of Statistics — singstat.gov.sg
  • Bank Negara Malaysia — bnm.gov.my
  • Malaysia Department of Statistics — dosm.gov.my
  • Bank Indonesia — bi.go.id
  • Statistics Indonesia — bps.go.id
  • Bank of Thailand — bot.or.th
  • State Bank of Vietnam — sbv.gov.vn
  • State Bank of Pakistan — sbp.org.pk
  • Pakistan Bureau of Statistics — pbs.gov.pk
  • Bangladesh Bank — bb.org.bd
  • Central Bank of Sri Lanka — cbsl.gov.lk
  • Nepal Rastra Bank — nrb.org.np
  • Saudi Central Bank — sama.gov.sa
  • Saudi General Authority for Statistics — stats.gov.sa
  • United Arab Emirates Government — u.ae
  • Central Bank of the UAE — centralbank.ae
  • Qatar Central Bank — qcb.gov.qa
  • Bank of Israel — boi.org.il
  • Israel Central Bureau of Statistics — cbs.gov.il
  • Central Bank of Turkey — tcmb.gov.tr
  • Turkish Statistical Institute — tuik.gov.tr
  • Government of Brazil — gov.br
  • IBGE (Brazil statistics) — ibge.gov.br
  • Central Bank of Brazil — bcb.gov.br
  • Government of Mexico — gob.mx
  • INEGI (Mexico statistics) — inegi.org.mx
  • Bank of Mexico — banxico.org.mx
  • Government of Argentina — argentina.gob.ar
  • INDEC (Argentina statistics) — indec.gob.ar
  • Central Bank of Argentina — bcra.gob.ar
  • Central Bank of Chile — bcentral.cl
  • Chile National Statistics Institute — ine.cl
  • DANE (Colombia statistics) — dane.gov.co
  • Bank of the Republic (Colombia) — banrep.gov.co
  • Central Reserve Bank of Peru — bcrp.gob.pe
  • INEI (Peru statistics) — inei.gob.pe
  • Australian Bureau of Statistics — abs.gov.au
  • Reserve Bank of Australia — rba.gov.au
  • Government of New Zealand — govt.nz
  • Stats NZ — stats.govt.nz
  • Reserve Bank of New Zealand — rbnz.govt.nz
  • Government of the United Kingdom — gov.uk
  • UK Office for National Statistics — ons.gov.uk
  • Bank of England — bankofengland.co.uk
  • Swiss Federal Administration — admin.ch
  • Swiss National Bank — snb.ch
  • Statistics Norway — ssb.no
  • Statistics Sweden — scb.se
  • Government of Canada — canada.ca
  • Statistics Canada — statcan.gc.ca
  • Bank of Canada — bankofcanada.ca